BISPECIFIC REAGENTS FOR AIDS THERAPY
    26.
    发明授权
    BISPECIFIC REAGENTS FOR AIDS THERAPY 失效
    双特异性试剂艾滋病治疗

    公开(公告)号:EP0479909B1

    公开(公告)日:1996-10-30

    申请号:EP90911182.5

    申请日:1990-06-29

    申请人: MEDAREX, INC.

    IPC分类号: C12P21/00 C12N5/00 A61K39/395

    摘要: Bispecific molecules which react both with the high-affinity Fcη receptor of human effector cells and with a virus or virus component are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against a viral target (e.g. HIV or HIV-infected cell). For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fcη receptor antibody and the CD4 molecule or CD4 binding domain of the envelope glycoprotein gp120 of HIV. Alternatively, bispecific antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a HIV-specific antibody such as anti-gp120 antibody. Targeted effector cells can be used to kill virus by cell mediated antibody dependent cytolysis.

    Monoclonal antibodies to Fc receptors for immunoglobulin G on human mono-nuclear phagocytes, bifunctional antibodies, target specific effector cells, targeted macrophages, and innunoassays
    28.
    发明公开
    Monoclonal antibodies to Fc receptors for immunoglobulin G on human mono-nuclear phagocytes, bifunctional antibodies, target specific effector cells, targeted macrophages, and innunoassays 失效
    抗人单核吞噬细胞免疫球蛋白G的Fc受体的单克隆抗体; 双功能抗体; 靶向特异性效应细胞; 有针对性的巨噬细胞和免疫测定。

    公开(公告)号:EP0629703A3

    公开(公告)日:1995-03-22

    申请号:EP94202572.7

    申请日:1987-07-07

    申请人: MEDAREX, INC.

    摘要: A human Fc receptor-specific monoclonal antibody is disclosed together with its mode of preparation. Binding of the antibody to Fc receptor is not blocked by human immunoglobulin G. The antibody binds to the high affinity Fc receptor for IgG on human monocytes at a receptor binding site distinct from the ligand binding site for Fc. A bifunctional antibody or a heteroantibody has an antigen binding region derived from an anti-Fc receptor antibody and an antigen binding region specific for a target epitope or cell; such antibody may target a macrophage when it is bound to surface Fc receptors of the macrophage. A target-specific effector cell expresses receptor for the Fg portion of IgG, has one antigen binding region derived from an anti-Fc receptor antibody and another specific for a target cell, and the aforesaid bifunctional or hetero-antibody is bound to the Fc receptor of the effector cell; such effector cell can be used in the therapy of cancers, allergies, infectious and autoimmune diseases, and in immunoassays.

    摘要翻译: 人Fc受体特异性单克隆抗体是用圆盘其制备方式一起游离缺失。 不阻止抗体与Fc受体的结合由人免疫球蛋白G的抗体结合在受体结合位点由对Fc配体的结合位点不同的高亲和力Fc受体IgG的人单核细胞。 双功能抗体或杂抗体具有抗原结合从在抗Fc受体抗体和特异于靶表位或细胞的抗原结合区衍生的区域; 当它被结合到表面上的巨噬细胞的Fc受体抗体寻求可以靶向巨噬细胞。 对于IgG的纤维蛋白原部分A靶标特异性效应细胞快车受体,具有从在抗Fc受体抗体和另一种特异于靶细胞的一个抗原结合区域,和上述双官能或杂抗体结合于Fc受体 效应细胞的; 求的效应细胞可以在癌症,过敏症,感染和自身免疫性疾病的治疗中使用,并在免疫测定。